GO:0050113 inositol oxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050113 (inositol oxygenase activity) is a biological process term that describes the oxidative cleavage of myo-inositol to D-glucuronic acid, the rate-limiting step of myo-inositol catabolism.
• The enzyme myo-inositol oxygenase (MIOX) is the only known enzyme that initiates myo-inositol catabolism in mammals, and its activity is highly conserved from Drosophila to humans.
• MIOX is predominantly expressed in the kidney, and altered MIOX activity has been linked to diabetic nephropathy, gestational diabetes mellitus, and other metabolic disorders.
• MIOX is a non-heme di-iron enzyme that requires a di-iron cluster and a substrate radical mechanism for catalysis.
• Loss of MIOX function in model organisms leads to accumulation of myo-inositol and defects in development and stress responses.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal role of MIOX in metabolic and renal diseases.
Description
GO:0050113, inositol oxygenase activity, is a biological process term that describes the enzymatic conversion of myo-inositol to D-glucuronic acid. This reaction is the first and rate-limiting step of myo-inositol catabolism, a pathway that controls cellular levels of myo-inositol and provides precursors for glucuronidation and other metabolic routes. The enzyme responsible, myo-inositol oxygenase (MIOX), is a non-heme di-iron protein that is highly conserved across eukaryotes, from Drosophila melanogaster to humans. In mammals, MIOX is most abundant in the kidney, where it plays a central role in inositol homeostasis and in the response to hyperglycemic stress. Researchers study inositol oxygenase activity because it sits at the intersection of inositol signaling, glucose metabolism, and oxidative stress. Dysregulation of MIOX has been implicated in diabetic nephropathy, gestational diabetes mellitus, and other metabolic conditions. In Drosophila, loss of MIOX function alters development and stress resistance, highlighting its evolutionary importance. Understanding the molecular mechanism, regulation, and disease relevance of GO:0050113 requires integrated approaches, including CRISPR-based gene editing, biochemical assays, and omics technologies. This article provides a research-grade overview of GO:0050113, covering its definition, mechanism, key genes, disease associations, and experimental methods. All statements are based on published literature and authoritative GO annotations.
inositol oxygenase activity At A Glance
| GO ID | GO:0050113 |
|---|---|
| GO term | inositol oxygenase activity |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Oxidative cleavage of myo-inositol to D-glucuronic acid |
| Enzyme | Myo-inositol oxygenase (MIOX) |
| Cofactor | Non-heme di-iron cluster |
| Tissue distribution | Predominantly kidney, also liver and other tissues |
| Pathway | Myo-inositol catabolism |
What Is GO:0050113?
Inositol oxygenase activity (GO:0050113) is defined as the catalytic activity that converts myo-inositol to D-glucuronic acid in the presence of oxygen. This reaction is the committed step of myo-inositol catabolism, and it is catalyzed by the enzyme myo-inositol oxygenase (MIOX). The activity is classified as a biological process because it represents a metabolic conversion that contributes to inositol homeostasis and glucuronic acid supply.
Why Is inositol oxygenase activity Important in Cell Biology?
Inositol oxygenase activity is critical because it controls the flux of myo-inositol into the glucuronic acid pathway, thereby influencing inositol signaling, glucuronidation, and cellular responses to stress. Dysregulation of this activity has been linked to diabetic complications, metabolic disorders, and developmental defects in model organisms. As the only known enzyme that initiates myo-inositol catabolism in mammals, MIOX represents a potential therapeutic target for diseases characterized by inositol imbalance.
• Regulates cellular myo-inositol levels, affecting phosphoinositide signaling and osmoregulation.
• Provides D-glucuronic acid for glycosaminoglycan synthesis and detoxification reactions.
• Implicated in diabetic nephropathy: MIOX expression is elevated in high-glucose conditions and contributes to renal injury.
• Altered MIOX activity is observed in gestational diabetes mellitus, suggesting a role in pregnancy-related metabolic stress.
• Loss of MIOX function in Drosophila leads to developmental defects and altered stress responses.
• MIOX is a non-heme di-iron enzyme, making it a model for studying metalloenzyme catalysis.
• Potential biomarker for metabolic diseases and a target for therapeutic intervention.
• Its activity intersects with redox balance and ER stress pathways.
• Conserved from invertebrates to mammals, enabling comparative studies.
• CRISPR-based models allow precise dissection of MIOX function in vivo.
What Happens During inositol oxygenase activity?
Substrate binding and activation
In simple terms: The enzyme grabs myo-inositol and prepares it for chemical modification.
MIOX binds myo-inositol in its active site, where a non-heme di-iron cluster is coordinated by conserved histidine and aspartate residues. The substrate is positioned for oxidative attack, and the di-iron center is reduced to enable oxygen activation.
Oxidative cleavage
In simple terms: Oxygen is used to break the inositol ring, producing glucuronic acid.
The activated oxygen species attacks the C1–C6 bond of myo-inositol, leading to ring cleavage and formation of D-glucuronic acid. This reaction is the rate-limiting step of myo-inositol catabolism and is unique to MIOX.
Product release and downstream metabolism
In simple terms: The product, glucuronic acid, is released and enters other pathways.
D-glucuronic acid is released from the active site and can be further metabolized in the glucuronate pathway, contributing to ascorbate synthesis in some organisms or to glucuronidation in mammals.
Regulation by substrate availability and stress
In simple terms: The speed of the reaction depends on how much inositol is available and on cellular stress.
MIOX activity is influenced by intracellular myo-inositol concentrations and by stress conditions such as hyperglycemia and ER stress. High glucose upregulates MIOX expression in renal cells, linking this activity to diabetic complications. ER stress pathways can also modulate MIOX function, integrating inositol catabolism with the unfolded protein response.
Key Genes Involved in GO:0050113 inositol oxygenase activity
The following genes and proteins are directly or indirectly involved in inositol oxygenase activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MIOX | Catalyzes the oxidative cleavage of myo-inositol to D-glucuronic acid | Central enzyme for GO:0050113; target for metabolic disease studies |
| IMPA1 | Involved in myo-inositol synthesis from glucose-6-phosphate | Regulates substrate availability for MIOX |
| IMPA2 | Involved in myo-inositol synthesis | May influence MIOX substrate levels |
| SLC5A3 | Sodium/myo-inositol cotransporter | Controls cellular myo-inositol uptake, affecting MIOX activity |
| SLC2A2 | Glucose transporter | Influences glucose flux and MIOX expression in kidney |
| AKR1B1 | Aldose reductase | Competes with MIOX for glucose metabolism in polyol pathway |
| TXN | Thioredoxin | Maintains redox balance affecting MIOX di-iron center |
| NFE2L2 | Nrf2 transcription factor | Regulates antioxidant response and may modulate MIOX expression |
| ATF4 | ER stress transcription factor | Links ER stress to MIOX regulation |
| XBP1 | ER stress sensor | Modulates MIOX under ER stress |
| DDIT3 | CHOP, ER stress-induced apoptosis | May influence MIOX-related cell death |
| HSPA5 | BiP, ER chaperone | Regulates ER stress and MIOX stability |
| KEAP1 | Nrf2 inhibitor | Modulates Nrf2-driven MIOX expression |
| SQSTM1 | p62, autophagy receptor | Links autophagy to MIOX regulation |
| MAP1LC3B | Autophagy marker | Monitors autophagy in MIOX-related studies |
| PRKAA1 | AMPK catalytic subunit | Energy sensor that may regulate MIOX |
| MTOR | mTOR kinase | Central regulator of metabolism, may influence MIOX |
How Is inositol oxygenase activity Regulated?
MIOX activity is regulated at multiple levels. Transcriptionally, MIOX expression is induced by high glucose and osmotic stress in renal cells, and this induction is mediated in part by transcription factors such as NFAT and CREB. The Nrf2 pathway, which controls antioxidant responses, can also modulate MIOX expression under oxidative stress conditions. At the post-translational level, the di-iron center of MIOX is sensitive to oxidative damage, and its activity can be modulated by cellular redox status. ER stress pathways, including the PERK-ATF4-CHOP axis, have been shown to influence MIOX expression and function, linking inositol catabolism to the unfolded protein response. Additionally, autophagy and ferritinophagy may affect MIOX turnover by regulating iron availability for the di-iron cluster.
inositol oxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MIOX | Diabetic nephropathy | MIOX knockout mice, kidney organoids |
| MIOX | Gestational diabetes mellitus | MIOX overexpression in placental cells |
| MIOX | Metabolic syndrome | Drosophila MIOX mutants |
| MIOX | ER stress-related organ injury | MIOX knockout in renal tubular cells |
| MIOX | Inositol imbalance disorders | MIOX knock-in with point mutations |
Diabetic nephropathy
MIOX is upregulated in the kidneys of diabetic patients and animal models, where it contributes to renal tubular injury and fibrosis. High glucose induces MIOX expression through osmotic and oxidative stress pathways, and MIOX-derived reactive oxygen species exacerbate kidney damage. Targeting MIOX activity may therefore be a therapeutic strategy for diabetic nephropathy.
Gestational diabetes mellitus
Altered myo-inositol catabolism, reflected by increased MIOX activity, has been observed in the second trimester of pregnancies complicated by gestational diabetes mellitus. This suggests that MIOX may serve as a biomarker or therapeutic target for this condition.
Metabolic disorders and inositol imbalance
Dysregulation of MIOX affects myo-inositol homeostasis, which is implicated in insulin resistance, obesity, and metabolic syndrome. In Drosophila, loss of MIOX leads to developmental defects and altered stress responses, highlighting the evolutionary importance of this pathway. Pharmacological modulation of MIOX activity is being explored for metabolic diseases.
ER stress and organ injury
MIOX activity is linked to ER stress-induced cell death pathways. ER stress can upregulate MIOX, and the resulting oxidative stress may contribute to organ injury in conditions such as acute kidney injury and liver disease.
From inositol oxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MIOX loss affect myo-inositol levels? | MIOX knockout cell lines and mice |
| How does a specific MIOX mutation alter catalytic activity? | Point-mutation knock-in via CRISPR |
| Can MIOX overexpression induce diabetic nephropathy? | MIOX overexpression in renal cells |
| What is the subcellular localization of MIOX? | Tagged knock-in with fluorescent protein |
| Which genes interact with MIOX in disease? | CRISPR library screening |
| How does MIOX activity change under ER stress? | MIOX knockout with ER stress inducers |
How to Study the inositol oxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| MIOX activity assay | Enzymatic conversion of myo-inositol to glucuronic acid | Kinetic studies, mutant validation |
| CRISPR knockout | Loss of MIOX function | Phenotypic studies in cells and mice |
| CRISPR knock-in | Introduction of specific mutations or tags | Structure-function analysis |
| RNA-seq | Transcriptional changes | Pathway analysis upon MIOX modulation |
| Proteomics | Protein expression and interactions | Identifying MIOX binding partners |
| Metabolomics | Levels of myo-inositol and glucuronic acid | Metabolic flux analysis |
| Immunofluorescence | Subcellular localization | MIOX trafficking studies |
| CRISPR library screening | Genome-wide modifiers of MIOX phenotype | Identifying synthetic lethal partners |
Biochemical assays for MIOX activity
MIOX activity is typically measured by monitoring the conversion of myo-inositol to D-glucuronic acid using colorimetric or chromatographic methods. These assays are essential for validating enzyme kinetics and the effects of mutations.
CRISPR-based gene editing
CRISPR-Cas9 is used to generate MIOX knockout, knock-in, and point-mutation cell lines and animal models. These models allow researchers to dissect the causal role of MIOX in metabolic and renal diseases.
Omics approaches
RNA-seq and proteomics can profile global changes in gene expression and protein abundance upon MIOX modulation. Metabolomics is particularly useful for measuring myo-inositol and glucuronic acid levels.
Imaging and localization studies
Fluorescent tagging of MIOX via knock-in enables live-cell imaging to determine its subcellular localization and dynamics under stress conditions.
How CRISPR Can Be Used to Study GO:0050113 inositol oxygenase activity
Knockout
CRISPR-Cas9 knockout of MIOX is used to completely abolish inositol oxygenase activity, allowing researchers to study the consequences of myo-inositol accumulation and loss of glucuronic acid production. MIOX knockout mice and cell lines have been generated to model diabetic nephropathy and metabolic disorders.
Point Mutation
Point mutations in the MIOX active site, such as those affecting di-iron coordinating residues, can be introduced via CRISPR-mediated homology-directed repair. These models help dissect the catalytic mechanism and identify residues critical for enzyme activity.
Knock-in
Knock-in of tagged MIOX (e.g., GFP or HA) enables real-time tracking of enzyme localization and interaction partners. Knock-in of disease-associated variants can also model human mutations in vivo.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of MIOX is used to mimic pathological upregulation observed in diabetic nephropathy. These models help establish causality between MIOX levels and disease phenotypes.
How EDITGENE Supports inositol oxygenase activity Research
Researchers studying inositol oxygenase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or renal phenotypes. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for inositol oxygenase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| MIOX Knockout HEK293 Cell Line | EDJ-KQ14268 | Human | 55586 | Details Get a Quote |
| MIOX Knockout HeLa Cell Line | EDJ-KQ56605 | Human | 55586 | Details Get a Quote |
| MIOX Knockout A-549 Cell Line | EDJ-KQ65104 | Human | 55586 | Details Get a Quote |
| MIOX Knockout HCT 116 Cell Line | EDJ-KQ73550 | Human | 55586 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About inositol oxygenase activity
What is inositol oxygenase activity?
Inositol oxygenase activity (GO:0050113) is the enzymatic conversion of myo-inositol to D-glucuronic acid, catalyzed by myo-inositol oxygenase (MIOX).
What genes are involved in inositol oxygenase activity?
The primary gene is MIOX, which encodes myo-inositol oxygenase. Other genes such as IMPA1, SLC5A3, and AKR1B1 influence substrate availability and pathway flux.
What is the role of MIOX in diabetic nephropathy?
MIOX is upregulated in diabetic kidneys and contributes to renal injury through oxidative stress and fibrosis.
How is inositol oxygenase activity regulated?
MIOX is regulated transcriptionally by glucose and osmotic stress, and post-translationally by redox status and ER stress pathways.
What diseases are associated with MIOX dysfunction?
MIOX dysfunction is linked to diabetic nephropathy, gestational diabetes mellitus, metabolic syndrome, and ER stress-related organ injury.
How can I study inositol oxygenase activity in the lab?
Common methods include enzymatic activity assays, CRISPR knockout/knock-in models, RNA-seq, proteomics, and metabolomics.
What model organisms are used for MIOX research?
Mice, rats, and Drosophila melanogaster are widely used. Drosophila MIOX mutants reveal developmental and stress response roles.
Is MIOX a potential therapeutic target?
Yes, MIOX is considered a therapeutic target for diabetic nephropathy and other metabolic diseases due to its role in inositol catabolism.
What is the catalytic mechanism of MIOX?
MIOX uses a non-heme di-iron cluster to activate oxygen and cleave the myo-inositol ring, producing D-glucuronic acid.
How does ER stress affect MIOX?
ER stress can upregulate MIOX expression through the PERK-ATF4-CHOP pathway, linking inositol catabolism to the unfolded protein response.
Conclusion
Inositol oxygenase activity (GO:0050113) is a fundamental biological process that controls myo-inositol catabolism and glucuronic acid production. The enzyme MIOX is highly conserved and plays critical roles in metabolic homeostasis, with dysregulation linked to diabetic nephropathy, gestational diabetes, and other diseases. Understanding its mechanism, regulation, and disease relevance requires integrated approaches, including CRISPR-based gene editing, biochemical assays, and omics technologies. EDITGENE provides comprehensive services to support research on MIOX and related pathways, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Sano R et al.. 2013. ER stress-induced cell death mechanisms.. Biochim Biophys Acta 1833(12):3460-3470 PMID: 23850759
- 2. Tang G et al.. 2021. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.. Acta Pharm Sin B 11(9):2749-2767 PMID: 34589395
- 3. Croze ML et al.. 2013. Potential role and therapeutic interests of myo-inositol in metabolic diseases.. Biochimie 95(10):1811-27 PMID: 23764390
- 4. Shao N et al.. 2026. Ferritinophagy and organ injury.. Autophagy 22(6):1171-1185 PMID: 41692973
- 5. Sharma RS et al.. 2018. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).. Cell Mol Gastroenterol Hepatol 5(3):367-398 PMID: 29552625
- 6. Contreras A et al.. 2023. Inositol in Disease and Development: Roles of Catabolism via myo-Inositol Oxygenase in Drosophila melanogaster.. Int J Mol Sci 24(4) PMID: 36835596
- 7. Kısa B et al.. 2022. Myo-inositol oxygenese activity in second trimester of pregnancy: altered myoinositol catabolism in gestational diabetes mellitus.. Arch Physiol Biochem 128(4):910-913 PMID: 32191130
- 8. Han S et al.. 2025. Myo-Inositol Oxygenase (MIOX): A Pivotal Regulator and Therapeutic Target in Multiple Diseases.. Curr Issues Mol Biol 47(9) PMID: 41020866
